In Pursuit Of Cash, OXiGENE Inc (NASDAQ:OXGN) Declares Bad Investor News

Boston, MA 05/27/2014 (wallstreetpr) – OXiGENE Inc (NASDAQ:OXGN) has announced plans to raise cash through equity offering. And as much as the move will help the company to improve its cash position, it is not the best of the news for the existing shareholders because it will inevitably result in value dilution. However, the long-term result […]

OXiGENE Inc’s (NASDAQ:OXGN) Ovarian Cancer Medicine Gets Orphan Drug Status in Europe

Boston, MA 07/22/2013 (wallstreetpr) – OXiGENE Inc (NASDAQ:OXGN) announced that the European Medicines Agency has forwarded orphan drug standing to its ovarian cancer cure, Zybrestat. The biopharmaceutical firm’s scrip zoomed 25 per cent to hit $3.12 after hours. Through the close, the scrip has declined 53 per cent since the beginning of 2013. The orphan drug standing […]